Diligence memo · auto-generated · as of July 2, 2026
Neurolutions Inc
Neurolutions Inc looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Neurolutions Inc operates in Biotechnology, based in VAN NUYS.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Neurolutions Inc has raised $27M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $27M on 2025-02-14.
Most recent recorded round closed around 2025-02-14.
Valuation (modeled)modeled
Provath models Neurolutions Inc at approximately $145M (range $53M–$230M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.87× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 17 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 73% of Biotechnology peers (4293 compared).
Modeled value ranks above 66% of those peers.
Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.